Mutant ALK has been therapeutically targeted in neuroblastoma with small molecular enzymatic inhibitors that have been implemented from the original discoveries of germline and somatic ALK mutations2,3,13,14, to preclinical proof-of-concept25,26, through early and late-phase clinical implementation27,28 (NCT03126916). The gene discussed is ALK; the disease is neuroblastoma.